Evidence map›Paper›PMID 42470405›Full record

ReviewJACC. Cardiovascular imaging2026

Understanding HFpEF Through Imaging: Strengths, Limitations, and Current State of the Art.

Tomonari Harada, Jwan A Naser, Fahime Ghanbari, Barry A Borlaug

Abstract readReview
In one paragraph

Review in JACC. Cardiovascular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Tomonari HaradaDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Jwan A NaserDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Fahime GhanbariDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Barry A BorlaugDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA. Electronic address: borlaug.barry@mayo.edu.

Funding

Pulmonary Hypertension in Left Heart DiseaseR01HL162828 · NHLBI · MAYO CLINIC ROCHESTER · PI Barry A. Borlaug, Margaret M Redfield · 2023 to 2026
$3.1M
HL-Inorganic Nitrite to Enhance Benefits from Exercise Training in Heart Failure with preserved Ejection FractionR01HL128526 · NHLBI · MAYO CLINIC ROCHESTER · PI BORLAUG, BARRY A. · 2016 to 2019
$2.4M
Mayo Clinic HeartShare Clinical CenterU01HL160226 · NHLBI · MAYO CLINIC ROCHESTER · PI Barry A. Borlaug, Margaret M Redfield · 2021 to 2026
$1.8M
NHLBI NIH HHS R01 HL128526NHLBI NIH HHS R01 HL162828NHLBI NIH HHS U01 HL160226
6 · The paper itself

Abstract

Heart failure with preserved ejection fraction (HFpEF) is a clinical syndrome characterized by dyspnea caused by hemodynamic congestion, which develops at rest or with exercise. Noninvasive diagnosis remains challenging, because resting diastolic pressures may be normal, and even when abnormal, currently applied noninvasive indices lack sensitivity. The pathophysiology of HFpEF extends far beyond diastolic dysfunction, and such complexity can be better understood through imaging. This State-of-the-Art Review emphasizes echocardiography and other noninvasive imaging approaches as the first-line tools for HFpEF evaluation, while linking multimodality imaging to invasive hemodynamics as a physiologic reference standard. The authors emphasize evidence-based, multiparametric assessment, where combined cardiopulmonary exercise testing with exercise stress echocardiography can quantify the diverse reserve limitations that characterize HFpEF, including cardiac and extracardiac contributors, atrial and right heart dysfunction, pulmonary vascular and ventilatory limitation, dynamic atrioventricular regurgitation, extrinsic restraint, pulmonary congestion, and peripheral impairments, acknowledging that such phenotyping must be anchored to actionable findings and evidence-based interventions. The authors describe the potential role of exercise cardiac magnetic resonance and artificial intelligence-enabled imaging analysis for phenotyping and risk stratification. Finally, the authors propose an echo-first Bayesian pathway that updates pretest to posttest probability and supports identification of patients in whom invasive hemodynamic exercise testing may be required to confirm the diagnosis and validate imaging markers against invasively measured congestion.

Indexed as

diastolic dysfunctionechocardiographyexercise stress echocardiographyheart failure with preserved ejection fractionhemodynamics

Identifiers

PMID42470405
PMCPMC13384203

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.